Antigenicity and immunogenicity of recombinant envelope glycoproteins of SIVmac32H with different in vivo passage histories. by Hulskotte, E.G.J. (Ellen) et al.
0264410X(95)000534 
kccine, Vol. 13, No. 13, pp. 1187-1197, 1995 
Copyright 0 1995 Elsevier Science Ltd 
Printed in Great Britain. All rights reserved 
0264-410X/95 $iO+O.OO 
Antigenicity and immunogenicity of 
recombinant envelope glycoproteins of 
SIVmac32H with different in vivo 
passage histories 
Ellen G.J. Hulskotte*, Guus F. Rimmelzwaanj-, Jolande Bees*, 
Marnix L. Bosch*$, Jonathan L. Heeneys, Stephen G. Norlefl, 
Petra de Vries* and Albert D.M.E. Osterhaus*j$ 
Shortly after infection of two rhesus monkeys (Macaca mulatta) either with a 
SIVmac32H challenge stock or with the same virus that had been passaged in another 
rhesus monkey for 1 I months, SIV-envelope genes were clonedfrom their peripheral blood 
mononuclear cells and subsequently expressed by recombinant vaccinia viruses. The 
molecular weights and antigenicities of the thus produced envelope glycoproteins were 
largely identical to those of the native SIV The envelope glycoprotein derivedfrom the in 
vivo passaged virus proved to be poorly recognized by virus neutralizing monoclonal 
antibodies directed against one of the seven antigenic sites for which monoclonal 
antibodies were available. Immunization studies in rats showed that this protein was also 
less eficient in inducing antibodies against this antigenic site, and that it induced 
signtficantly lower levels of virus neutralizing antibodies than the other SW-envelope 
glycoprotein. The immunogenicity of the SIV-envelope glycoprotein incorporated into 
immune stimulating complexes (iscoms) was compared to that of the same protein 
presented with Quil A or MDP-tsl. 
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Simian immunodeficiency virus (SIV) and human 
immunodeficiency virus (HIV) are closely related lenti- 
viruses which show similarities both in their genomic 
organization and in the disease they cause in their 
respective hosts’. Therefore SIV infection of macaques 
is considered a suitable model for HIV infection in 
humans to study pathogenesis and development of 
passive and active immunization strategies. 
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The envelope gene encoded surface (SU) and trans- 
membrane (TM) glycoproteins of lentiviruses play a 
crucial role in virus attachment and fusion to host 
cells, and serve as targets for virus neutralizing (VN) 
antibodies and helper and cytotoxic T cells (for review 
see Ref. 2). Therefore, the inclusion of these envelope 
glycoproteins in candidate vaccine preparations in a 
form that stimulates both cellular and humoral 
immunity is desirable. 
In several studies SIV candidate vaccines have been 
tested for their ability to induce protective immunity 
against challenge with SIV. Although in many of these 
studies induction of protective immunity by candidate 
SIV vaccines was reported, it was shown that in most 
cases an anti-cell rather than an anti-virus response was 
at the basis of this protection”. We have shown that after 
vaccination with envelope glycoprotein enriched whole 
SIVmac, four of the eight vaccinated animals were 
protected against an intravenous challenge with SIV- 
infected peripheral blood mononuclear cells (PBMC)4.5. 
So far, in SIV experiments there has been only one 
report describing protection induced with a recombinant 
vaccine preparation6. In this study priming with live 
recombinant vaccinia virus expressing the envelope pro- 
tein followed by boosting with recombinant envelope 
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protein expressed by baculovirus, resulted in protection 
of rhesus macaques against a homologous challenge 
with a molecular clone of SIVmne. In the SIVmac 
model system, immunization with recombinant SlV 
preparations led to a reduced virus load7.8. 
Successful vaccines against lentivirus infections 
should at least provide protective immunity against 
homologous viruses and related variants. This may be 
achieved by the induction of immune responses directed 
to conserved regions of the envelope protein involved in 
VN, or by the simultaneous induction of immune re- 
sponses to variable regions on the envelope protein of 
different variant viruses. In the present study, we de- 
scribe the analysis of the antigenicity and immunogenic- 
ity of the envelope protein of SIVmac32H and its 
counterpart which had undergone an in vivo passage of 
11 months. For this purpose, recombinant envelope 
proteins were obtained from PBMC of two monkeys 
shortly after infection with the respective viruses, to 
select for envelope sequences which are related to viruses 
which actually establish infection. 
MATERIALS AND METHODS 
Virus 
SIV-env sequences were analyzed from two rhesus 
monkeys (Macaca mulatta), numbers 8672 and 8789. 
These animals belonged to control groups of animals 
in a previous SIV vaccination study5. Macaque number 
8789 had been inoculated intravenously with 10 MID5o 
of the 32H isolate of SIVmac251 (1 l/88 pool)“,‘“. The 
monkey died from AIDS-like symptoms 26 weeks post- 
infection. Macaque number 8672 was inoculated intra- 
venously with 10 MID,, of SIV-infected PBMC derived 
from rhesus macaque number 1XC. PBMC of number 
1XC were isolated 11 months post-infection with an 
intravenous dose of 50 MID,, of the 32H isolate of 
SIVmac251 (pool 1 l/88)“. Macaque number 8672 died 
from AIDS-like symptoms 39 weeks post-infection. 
PBMC were isolated from macaques numbers 8789 
and 8672 two and four weeks post-infection, respec- 
tively, and used for sequence analysis. At these time 
points no SIVmac32H specific VN serum antibodies had 
developed in the respective monkeys5. 
DNA template preparation 
PBMC of rhesus macaques numbers 8789 and 8672 
were resuspended in a buffer containing 50 mM KCl, 10 
mM Tris-Cl (pH 8.4). 1.5 mM MgCl,. 0.5% Tween-20 
and 100 ,ug ml-’ proteinase K at a concentration of 
1 x 10’ cells ml-] and incubated for 16 h at 54°C 
followed by 10 min at 95°C. The resulting cell lysate was 
used as source of template DNA in subsequent PCR 
amplifications. 
PCR amplification 
As the number of infected cells in PBMC of SIV- 
infected macaques early in infection was expected to be 
low, a nested primer PCR was developed to obtain 
sufficient quantities of DNA for cloning. Primers for 
PCR were chosen which recognized conserved sequences 
flanking the SIVmac envelope gene sequence (Los 
Alamos AIDS database). Outer set of primers: 5’-GGC 
CAACCTGGGGGAGGAAATCC-3’ (6398); 5’-GCA 
CTGTAATAATCCCTTCCAGTCCCCCC-3’ (9481). 
Inner set of primers: 5’-CGCGTCGACGTAAGTAT 
GGATGTCTTGGGAATCAGC-3’ (6599); 5’-GACCC 
CGGGCCCCTGATTGTATTTCTGTCCC-3’ (9264). 
The positions of the 5’-nucleotide in the SIVmac32H-J5 
molecular clone are indicated in parentheses. SmaI and 
Sal1 restriction sites (presented in bold) were incorpor- 
ated near the 5’ ends of the inner primer set to facilitate 
subsequent cloning. These sites were chosen from a list 
of “non-cutters” generated after analysis of the SIV- 
mac251 sequence. Ten microlitres of the cell lysate were 
added to a PCR reaction mixture containing 10 mM 
Tris-Cl (pH 8.4), 50 mM KCl, 1.5 mM MgCl,, 200 pg 
ml-’ gelatin, 200 PM of each dATP, dCTP, dGTP and 
dTTP, 0.1 yM of each primer of one primer set and 2.5 
units Taq polymerase (AmpliTaq, Cetus, Emeryville, 
CA). The total reaction volume of 100 ~1 was overlaid 
with mineral oil. DNA was amplified by a 4 min 94°C 
denaturation step followed by 36 cycles comprising 
denaturation at 94°C for 1 min, annealing at 53°C for 1 
min and extension at 72°C for 2 min. Reamplification of 
10 ~1 of the first PCR was performed with the inner set 
of primers under the same reaction conditions for 40 
cycles. 
Molecular cloning and sequence analysis 
PCR reaction mixtures were extracted once with 
phenol/chloroform and concentrated on an Amicon- 
filter (Amicon). DNA was subsequently analyzed on a 
0.9% agarose gel, the presumed 2.6 kb enveIope frag- 
ment was purified and digested with SalI and SmaI and 
cloned into Sal1 and SmaI digested cloning vector pB- 
IuescriptII SK(+) (Stratagene, La Jolla, CA). Sequenc- 
ing was carried out using a multiwell microtitre plate 
DNA sequencing system (Amersham) based on the 
dideoxynucleotide chain termination sequence reaction. 
The nucleotide and protein alignments were determined 
with Lasergene software (DNAstar Inc., London, UK). 
Nucleotide sequence accession numbers 
Nucleotide sequences of clones 8672-20 and 8789-l 1 
have been submitted to GenBank and are avail- 
able under accession numbers L35596 and L35597, 
respectively. 
In vitro mutagenesis 
In order to mutate the presumed primary and second- 
ary cleavage site of the precursor envelope protein”, 
amino acid substitutions were made by site-directed 
mutagenesis (primary cleavage site: RNKR to RNSA; 
secondary cleavage site: KR to KS) using three 
PCR reactions. The pBSf constructs containing the 
respective envelope genes were used as template 
DNA. Primers 5’-mut (5’-GTGAAGAGcTACACTA 
CTGGTGGCACCTCAAGAAATAgcgcAGGGG TCT 
TTGTGC (8135)) and 3’-NcoI (5’-GCATTTGGCCAT 
GGTACAGTAGTGTGGC-3’ (8478)) were used to ob- 
tain fragment 5’-mut/3’-NcoI. Using primer pair 3’-mut 
(5’-GCACAAAGACCCCTgcgcTATTTCTTG AGGTG 
CCACCAGTAGTGTAgCTCTTCAC-3’, reverse com- 
plementary to 5’-mut) and 5’-ClaI (5’-GGCAGAAC 
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TATCGATTGGAATTGGG-3’ (8059)) fragment 5-‘ClaI/ 
3’-mut was obtained. The positions of the 5’-nucleotide in 
the SIVmac32H (J5) sequence are indicated in parentheses. 
The lower case letters represent nucleotide changes that 
were introduced. Subsequently, the 5’-ClaI/3’-mut and 5’- 
mut/3’-NcoI fragments were used as template in a PCR 
using primers 5’-ClaI and 3’-NcoI. The PCR-derived 5’- 
ClaI/3’-NcoI fragment including the nucleotide substitu- 
tions was purified by preparative gel electrophoresis, 
digested with ClaI and Ncol and cloned into ClaI and NcoI 
digested clones 8672-20 and 8789-l 1, respectively. The 
presence of the substitutions was confirmed by sequence 
analysis. The mutated envelope proteins were designated 
8672-m and 8789-m, respectively. 
(n-octylpolyoxyethylene, 
Rosenbuch-Tenside; Bachem, Bubendorf, Switzerland) 
at a concentration of 2 X 10’ cells ml-’ for 90 min at 4°C. 
The cell lysate was centrifugated for 15 min at 2500 revs 
min-‘. Glycoproteins were allowed to adsorb to lentil 
lectin sepharose (Pharmacia LKB, Uppsala, Sweden) 
overnight. Subsequently, the lentil lectin sepharose was 
washed with buffer A (10 mM Tris-HCl pH 7.410.3 M 
NaCl/O.S% RBT) followed by washing with buffer B 
(buffer A supplemented with 10 pug ml-’ of the lipids 
cholesterol and phosphatidylcholine (Sigma, St. Louis, 
USA)). Bound glycoproteins were eluted with buffer C 
(buffer B containing 0.5 M cl-methylmannopyranoside). 
Quantification of SIV-envelope glycoproteins was 
performed as described previously’. 
Formulation of antigen preparations and immunization 
schedule in rats 
For the preparation of immune-stimulating complexes 
(iscoms) lentil lectin enriched 8672-m or 8789-m proteins 
were mixed with the lipids cholesterol and phosphatidyl- 
choline (Sigma; stock 10 mg ml’ in 10% MEGA-IO 
(Boehringer Mannheim, Mannheim, Germany)) and 
Quil A (Spikoside, Iscotec, Lulea, Sweden) at a ratio of 
1: 1:5 (w/w/w). After ultrasonic treatment for 10 min the 
mixture was incubated for 1 h at room temperature 
(RT). Subsequently, the mixture was extensively dia- 
lysed against 10 mM Tris-HCl pH 7.4/0.3 M NaCl, 
layered over a linear (lo-60%) sucrose padient and 
centrifugated (18 h at 25 000 revs mine . Beckmann 
SW28 rotor). The gradient was fractionated and frac- 
tions were analyzed for the presence of envelope protein 
by enzyme-linked immunosorbent assay (ELISA). Frac- 
tions containing peak levels of the envelope protein 
(coinciding with the presence of iscom-like structures, as 
judged by electron microscopy) were pooled. 
For the Quil A and MDP-tsl antigen preparations, 
3 pg of lentil lectin enriched SIV-env 8789-m was adju- 
vanted either with 10 pg Quil A (Spikoside, Iscotec) or 
0.5 ml MDP-tsl (0.462 ml PBS containing 12.5 lug MDP 
(muramyl dipeptide) (Sigma), 1 ~1 Tween-80, 25 ~1 
squalene and 12.5 ~1 of the plutonic block polymer LlOl 
(Serva, Heidelberg, Germany))‘5,16. 
Female rats (RIV:tox) were divided into groups of 
four animals and were immunized intramuscularly (i.m.) 
with the different antigen preparations and boosted 
four weeks later with the same material. Each rat 
received 3 ,ug of rgp160 per immunization except for the 
rats immunized with both 8672-m and 8789-m incor- 
porated into iscoms. These received 3 pg of each rgp160 
construct per immunization. Serum samples were 
collected before and 2, 4, 5, 6, 8, and 14 weeks after the 
first immunization. 
Western blotting 
Procedures for western blotting were performed as 
described previously’. 
Binding of monoclonal antibodies (Moabs) to different 
SIV-envelope preparations 
Multiwell plates (Costar, Cambridge, USA) were 
coated with 100 ~1 PBS containing 200 pg ConA and 
then incubated with the different SIV-envelope prepar- 
ations at a concentration of 10 ng envelope protein in 
100 ,ul PBS containing 1% RBT, for 16 h at RT. Wells 
were blocked with PBS containing 0.1% Tween-20 and 
1% BSA (PTB) supplemented with 10% FCS, and sub- 
sequently incubated for 2 h at RT with threefold serial 
dilutions starting at 1:200 of one of the env-specific 
Moabs (ascitic fluid, kindly provided by Dr K. Kent). 
Plates were washed and incubated with biotin conju- 
gated goat-anti-mouse IgG (Amersham) and horse 
radish peroxidase (HRPO) conjugated streptavidine 
(Amersham). The substrate reaction was carried out 
with 3,3’,5,5’-tetramethyl-benzidine’7. The antibody 
titre was defined as the reciprocal of the dilution of the 
Moab giving 50% of the maximum O.D.,,e obtained for 
that Moab and was determined from three independent 
experiments. Values two times that of similarly proc- 
essed preparations of vSC65-infected BHK cells were 
considered positive. 
Whole SIV ELISA to demonstrate envelope-specific 
antibodies 
ConA coated multiwell plates were incubated with 
50~1 of SIV-infected C8166 cell lysate5 in PBS/l% triton 
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containing 70 ng ml“ SIV-env, for 16 h at RT. (Quanti- 
fication of the SIV-envelope protein was performed as 
described previously’.) Wells were blocked with PTB 
containing lo”/0 FCS and subsequently incubated with 
50 ~1 of twofold dilutions of rat serum in PTB contain- 
ing 4% FCS. After 2 h incubation at RT, wells were 
washed and bound antibody was detected using a rabbit- 
anti-rat lg-HRPO antibody preparation (DAKO, 
Glostrup, Denmark). The substrate reaction was carried 
out as described above. Endpoint titres were calculated 
using a cut-off value twofold above the respective 
dilution of the pre-immune serum at O.D.,,,. Antibodies 
with specificity for BHK cell components in the 
immunogen did not react with plate bound C8166 cell 
components. Comparison of titres between groups 
was conducted using a one-way analysis of variance 
(Anova; Minitab Inc., State college, USA). Titres were 
considered significantly different if ~~0.05. 
SW-envelope specific Moab inhibition ELISAs 
Inhibition ELlSAs were carried out as described pre- 
viously5 with minor modifications. Briefly, ConA coated 
multiwell plates were incubated with 100 ~1 C8166-SIV 
cell lysate containing 70 ng ml-’ SIV-envelope proteins. 
One hundred microlitres of twofold dilutions of rat 
serum were incubated for 1 h at RT. Subsequently, 50 ~1 
was taken out and wells were supplemented with 50 ~1 of 
Moab in PTB containing 4% FCS. Only Moabs with VN 
activity were used for these inhibition studies. It has 
been shown that Moabs KK5 and KK9 of competition 
group 1, which recognize a conformation dependent 
epitope, do not interfere with the binding of the SIV 
envelope protein to sCD4 as demonstrated in immuno- 
precipitation assays1x.3’. The Moabs were diluted to give 
an absorbance at 0.D.,5,, of 50-70% of the maximum 
absorbance in an indirect SIV-ELISA. Plates were incu- 
bated with a biotin-conjugated goat-anti-mouse IgG 
antibody preparation (Amersham) in PTB containing 
4% FCS and 5% normal rat serum (NRS), which 
was pre-incubated in this buffer for 1 h at RT, and 
subsequently with HRPO conjugated streptavidine 
(Amersham). The anti-mouse biotin IgG antibody 
preparation did not cross-react with rat lg in this assay. 
Inhibition titres were defined as the dilution of rat serum 
inhibiting 50% of the absorbance measured without 
competing antibody. The difference in titre between the 
different immunization groups was evaluated through a 
student’s t-test. Differences of ~~0.05 were considered 
significant. 
SW neutralization assay 
The SIV neutralization assay using SlVmac32H was 
performed as described previously’. Briefly, 10 ~1 of 
different dilutions of heat inactivated sera were incu- 
bated (four replicates per dilution) with 10 ~11 of 
SlVmac32H diluted to give ten infectious particles per 
10 ~1. After 30 min incubation at 37”C, 200 ~1 of media 
containing 2000 C8166 cells was added to each well of 
the microtitre plate. Plates were incubated for seven days 
at 37°C after which cells from each well were transferred 
to poly-L-lysine coated flat bottom microtitre plates, 
fixed in methanol, and examined for the presence of 
SlVmac-infected cells using a SIV-specific immuno- 
peroxidase assay. Wells containing no infected cells were 
scored as negative and the number of negative wells was 
used to determine the neutralizing dose 50% end-point 
(ND,,) for that serum by the method of Spearmann- 
Karber. The difference in titre between the different 
immunization groups was evaluated through a student’s 
t-test. Differences ofp<0.05 were considered significant. 
RESULTS 
Selection of SIV-envelope glycoproteins and sequence 
comparison 
PBMC were collected from two rhesus macaques, 
two weeks (monkey number 8789) or four weeks (mon- 
key number 8672) after infection with SlVmac32H. The 
first animal had been infected with 10 MID,, of the 
cell-free virus (1 l/88 pool) and the second with 10 
MID,,, of the PBMC from a monkey 11 months after 
infection with the 11/88 pool’. Representative SIV 
envelope genes were derived from the respective 
monkeys. SIV envelope clone 8789-l 1 was selected with 
a sequence shared by five of six clones in the variable 
regions 1 and 2 (VI and V2)19 and clone 8672-20 was 
selected from a panel of three clones which showed 
considerable similarities in this region with the exception 
of single amino acid differences. The predicted amino 
acid sequences of clones 8672-20 and 8789-l 1 are out- 
lined in Figure I, where they are compared with that of 
the consensus sequence of the envelope glycoprotein 
present in the 11188 stock of the 32H isolate of SIV- 
mac251 as identified by Almond et al.‘” As expected the 
8789-l 1 sequence showed much more similarity to the 
consensus sequence of the envelope glycoprotein present 
in the 32H isolate than the 8672-20 sequence (3 and 19 
amino acid differences, respectively). A 98% overall 
amino acid sequence identity was shown between clones 
8672-20 and 8789-l 1. Most strikingly, in the Vl region 
of the 8672-20 envelope sequence an extended sequence 
was found that was rich in serine and threonine residues, 
leading to a sequence commonly found in heavily 
O-linked glycosylated proteins”‘. An extra potential 
N-linked glycosylation site was found in clone 8672-20 
directly N-terminal of the start of the Vl region. In 
addition. two amino acid differences were found in the 
V2 region, one in the V4 region, four amino acid differ- 
ences outside the variable regions of the SU and five in 
the TM part of the SIV-envelope precursor sequence 
(Figure I). 
Expression of SIV-envelope glycoproteins by rVVS 
The RNKR sequence in clones 8672-20 and 8789-l 1, 
representing the cleavage site between the SU and TM 
part of the envelope genes, together with a second 
conserved cluster of basic amino acids which may 
serve as a secondary cleavage site”, was modified 
by site-directed mutagenesis. Subsequently, rVVs 
were generated from the parental 8672-20 and 
8789-11 envelope genes (designated ~8672 and ~8789, 
respectively) and from the cleavage site mutated 
envelope genes (designated v8672-m and v8789-m, 
respectively). 
Western blot analysis of BHK cells infected with 
~8672 using a TM-specific Moab, revealed proteins with 
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Figure 1 Predicted amino acid sequences of the envelope precursor protein of clones 8672-20 and 8789-11. They are aligned with the 
consensus sequence for the envelope glycoprotein present in the BPH-isolate of SIVmac251 (11/88 pool) as identified by Almond eta/.“Adash 
indicates that the amino acid is identical to the consensus sequence; variation in sequence is given in single letter code. Amino acid positions 
where no equivalent is present are indicated by a dot. The regions of the envelope protein equivalent to the variable regions (V) of HIV-1 are 
indicated34. The predicted cleavage site between the SU and TM part of the envelope protein is indicated. Potential N-linked glycosylation sites 
(N-X-S or N-X-T) are indicated in bold type 
molecular sizes of 160 and 41 kDa (Figure ZB, lane 2). 
The 160 kDa protein was also recognized by the SU 
membrane specific Moab (Figure 24 lane 2). In the 
culture medium a protein with a Mr of about 120 kDa 
was recognized by the gpl20-specific Moab (Figure 24. 
These data indicate that, like in the native protein, a 
160 kDa SIV precursor protein is synthesized which is 
processed to a 41 kDa TM protein and a 120 kDa SU 
protein which is also released into the medium. In 
v8789-infected BHK cells the 160 kDa envelope pre- 
cursor protein was predominant. In the culture medium 
the SU envelope glycoprotein was detectable. In the 
culture medium of cells infected with v8672-m and 
v8789-m containing the mutated envelope genes, no 
indication for the presence of the SU envelope glyco- 
protein was found. 
Incorporation studies with lentil lectin purified 
extracts from BHK cells infected with either of the rVVs, 
showed that iscoms prepared with the cleavage site 
mutated recombinant envelope proteins contained the 
gp160 precursor protein (Figure 3). 
Antigenicity of recombinant envelope glycoproteins 
8672, 8672-m, 8789, 8789-m and envelope glycoprotein 
derived from SIVmac32H 
Antigenicity of the envelope proteins expressed by 
~8672, v8672-m, ~8789 and v8789-m incorporated into 
iscoms was assessed with a panel of 15 SIV-envelope 
specific Moabs divided over seven competition 
groups”.” (see Figure 4). The antibody titre at which 
50% of the maximum 0.D.450 was obtained, was similar 
for all Moabs tested comparing the envelope glycopro- 
teins derived from SIVmac32H-infected C8 166 cells and 
rVV 8789 expressed envelope glycoprotein. Envelope 
glycoproteins derived from ~8672 were poorly recog- 
nized by Moabs of competition group 1 compared to 
envelope glycoproteins derived from ~8789 or SIV itself. 
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Figure 3 Western blot analysis of iscoms prepared with lentil-lectin 
purified proteins derived from v8672-m and v8789-m infected BHK 
cells using a gp120 specific monoclonal antibody (KK13) (A) or a 
gp41 specific monoclonal antibody (KK20) (B). The location of the 
envelope precursor protein (pre) as well as the mobilities of molecu- 
lar weight markers are indicated 
Interestingly, all Moabs of this competition group rec- 
ognize a conformational epitope and have been shown 
to possess VN activity”.“. 
No differences were found in the binding of the 
Moabs to the 8672 and 8789 envelope proteins in their 
native or cleavage site mutated form, except for one of 
the Moabs of competition group 7, KK16, which hardly 
recognized the 8789-m envelope protein. 
No changes in binding of the Moabs to the recom- 
binant envelope glycoproteins were found as a conse- 
quence of either paraformaldehyde fixation, lentil-lectin 
purification, or incorporation into iscoms (data not 
shown). 
Immunogenicity of recombinant envelope glycoproteins 
8672-m and 8789-m 
The immunogenicity of the 8672-m and 8789-m en- 
velope glycoproteins incorporated into iscoms was 
analyzed by immunizing laboratory rats. The overall 
kinetics and levels of SIV-specific antibody titres in- 
duced by immunization with two times 3 ,ug of one of the 
envelope glycoproteins proved to be similar when meas- 
ured by a whole SIV ELISA. Rats immunized with both 
iscom preparations (3 pg envelope protein of each per 
immunization) showed a significantly higher antibody 
response (Figu~ 5A). Inhibition of the Moab KK56 
could only be clearly demonstrated with sera from rats 
immunized with 8789-m envelope glycoproteins (Figure 
5B). This inhibition pattern of KK.56 was representative 
of all Moabs of competition group 1 (data not shown). 
Apparently there is a direct relationship between the 
recognition or presence of certain epitopes and their 
capacity to induce specific antibodies. VN serum anti- 
body titres of 8789-m iscom immunized rats were also 
significantly higher than those of 8672-m iscom immu- 
nized animals (Figure 50. Similar levels of VN serum 
antibodies and KK56 inhibition titre were found in rats 
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immunized with the 8789-m envelope proteins alone 
or in combination with the 8672-m envelope protein 
(Figure 5B, C). 
Immunogenicity of SIV-envelope glycoprotein 8789-m 
presented in the context of different adjuvant systems 
The effect of different adjuvant systems on the immu- 
nogenicity of the 8789-m envelope glycoprotein was 
studied by immunizing rats twice with 3 pug of this 
protein using Quil A, MDP-tsl or iscoms as adjuvant 
systems. Only rats immunized with envelope proteins 
adjuvanted with MDP-tsl showed a detectable antibody 
response after one immunization. After boosting, the 
highest envelope antibody titres measured by ELISA 
were seen with sera from rats immunized with the 
8789-m envelope glycoprotein incorporated into iscoms 
@=0.07, Figure 6A). There proved to be little decrease in 
serum antibody titres during the observation period, 
irrespective of the adjuvant used. The KK56 antibody 
inhibition titre as well as the VN serum antibody titre of 
rats immunized with the iscom-adjuvanted envelope 
glycoprotein were higher than those of rats immunized 
with envelope protein adjuvanted with Quil A or 
MDP-tsl, although only the difference in KK56 inhi- 
bition titres between sera from rats immunized with 
iscom and MDP-tsl adjuvanted glycoproteins proved to 
be significant (Figure 6B, C). 
DISCUSSION 
In the present study, we have shown that the anti- 
genicity and immunogenicity of two envelope glyco- 
proteins derived from the same parent virus, 
SIVmac32H, with different in viva passage histories 
differed considerably: the envelope protein derived from 
PBMC of a monkey infected with a virus which had 
undergone an extra in viva passage for 11 months was 
not recognized by a group of VN antibodies able to bind 
to the envelope protein of the parent virus, SIVmac32H. 
Upon immunization, this envelope protein failed to 
induce antibodies which could compete with these 
monoclonal antibodies for binding to the envelope 
protein of SIVmac32H. Concurrrently, a lower total 
VN antibody titre against SIVmac32H was induced 
in comparison to that induced by the envelope pro- 
tein derived directly from a SIVmac32H-infected 
monkey. 
There are several indications that conformational 
epitopes are involved in eliciting SW-neutralizing anti- 
bodies. SIV synthetic peptides proved to be poor in- 
ducers of VN antibodies, whereas immunization of 
macaques with recombinant envelope protein gp 110 
elicited strong VN antibodies”. Furthermore, VN activ- 
ity in sera from infected macaques could be absorbed 
out with native gpl10, but not with reduced or de- 
natured gp110Z3. Therefore, we chose the eukaryotic 
rVV expression system for the production of SIV- 
envelope glycoproteins to be incorporated in SIV candi- 
date vaccines. Vaccinia virus infectivity was eliminated 
by paraformaldehyde treatment. Although paraformal- 
dehyde is able to alter the antigenic structure of mem- 
brane protein?, no differences in antigenicity were 
found in the SIV-envelope protein before and after 
paraformaldehyde fixation (Hulskotte et al.. manuscript 
in preparation). The SIV 160 kDa envelope precursor 
proteins, expressed by rVV ~8672 and ~8789, were 
similarly cleaved to a 120 kDa SU and 41 kDa TM 
protein as in XV-infected cells, although cleavage of 
especially 8789-em proved to be less efficient. No 
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differences in antibody reactivities of a panel of 15 
Moabs with envelope glycoproteins derived from 
SIVmac32H-infected C8 166 cells and ~8789 expressed 
envelope glycoprotein were found indicating that the 
rVV expression system is able to produce SIV-envelope 
glycoproteins in their native conformation. 
Comparison of the amino acid sequences of 8672-20 
and 8789-l 1 envelope precursor proteins revealed a 98% 
amino acid similarity. It is interesting to note that in the 
Vl region of the 8672-20 sequence-derived from the in 
vivo passaged SIV-a T-rich stretch was inserted com- 
pared to the 8789-l 1 sequence. In SIVmne such a T-rich 
stretch was observed to be more common late in infec- 
tion’5.‘6. Sequential sequence analysis of the envelope 
genes derived from these monkeys provided strong evi- 
dence that such T-rich stretches emerge later in infection 
by active selection, indicating expression in vivo”“. The 
presence of this T-rich sequence in the envelope protein 
derived from PBMC of a monkey four weeks post- 
infection with an in vivo passaged virus indicates that 
sequence variation has most likely occurred during the 
11 months of in vivo passage of SIVmac32H in monkey 
1XC. In addition, at four weeks post-infection a hom- 
ogenous population of envelope sequences has been 
demonstrated in both HIV and SIV infection’7m30. 
The 8672 envelope glycoprotein was poorly recog- 
nized by all VN Moabs directed to a conformation 
dependent epitope on the surface protein (KK5, KK9, 
KK56). A recent study suggests that the V4 region is 
involved in the recognition of the SIVmac239 envelope 
protein by Moabs KK5 and KK9, as demonstrated 
by an amino acid substitution at position 419 (equiva- 
lent position in SIVmac32H sequence, Figure I), or 
deletions of four amino acids (position 421424 and 
1194 Vaccine 1995 Volume 13 Number 13 
fmmunogenicity of SIV gp160: E.G. J. Hulskotte et al. 
2048 
36450 6 
12150 
t!? 
.G 4050 
s .ZZ 
a 
r 
.c 1350 
: 
Z 
450 
150 
<50 
B 
3 
< 2.5 
0 6 0 6 0 6 
weeks post primary immunization C 
5; 512 
0 
5 
E 128 
C 
L 
(I) 32 
.- 
5 
8 
* lscom 
m quilA 
n MDP-tsl 
6 8 10 12 14 16 78 
weeks post primary immunization 
0 6 0 6 0 6 
weeks post primary immunization 
QuilA m MDP-tsl lscom 
Figure 6 SW-envelope antibody development in rats immunized with 8789-m envelope glycoproteins using different adjuvant systems. Mean 
titres were calculated from four rats immunized with the same adjuvant. Legends to Figure 6A, B and C are as for Figure 5A, B and C, 
respectively 
position 423427) in this region’. We also found a 
difference in the amino acid sequence between the 8789 
and 8672 envelope proteins in the same region in which 
the deletions were made”’ (K to N at position 423). 
However, a possible role for the other amino acid 
differences found between clone 8672 and 8789 in the 
recognition by the respective Moabs cannot be excluded 
and may be implicated in an escape mechanism from 
neutralization by antibodies which had developed in 
the macaque which donated the challenge material for 
monkey number 8672. 
No difference between the two envelope proteins was 
observed in binding of the other Moabs, including the 
VN antibodies KKlO and KK54”,“. However, in con- 
trast to the VN antibodies of competition group 1, 
binding of the VN Moabs KKlO and KK54 could 
neither be inhibited by the respective rat sera, nor by 
sera from monkeys immunized with the envelope glyco- 
proteins 8672-m and 8789-m incorporated into iscoms, 
nor by sera from SIVmac-infected monkeys (data not 
shown). However, it has been shown by others that sera 
from some SIVmac-infected macaques”.‘” and some 
macaques immunized with virus-derived gp130 in 
incomplete Freund’s adjuvant with or without prior 
priming with live rVV expressing the SIVmacBK28 
envelope protein, react with the peptide epitopes of these 
Moabs”“. 
To facilitate incorporation of the hydrophilic SU 
protein into iscoms, cleavage site mutated envelope 
proteins were expressed by rVVs. As mentioned above, 
the 8789 envelope glycoprotein was inefficiently cleaved 
exhibiting most of the envelope glycoprotein as the 
uncleaved precursor. However, we decided to also 
mutate this construct to obtain a uniform and well 
defined product. Indeed, the cleavage site mutated 
envelope glycoproteins, 8789-m and 8672-m, were 
efficiently incorporated into iscoms, which has also been 
demonstrated for the cleavage site mutated precursor 
envelope glycoprotein of FIVIJ. 
No differences in antibody reactivity of a panel of 15 
Moabs were found between the wild type and cleavage 
site mutated 8672 and 8789 envelope glycoproteins, 
except for the abrogated recognition of the 8789-m 
protein by Moab KK16. Sequence analysis showed that 
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during PCR used for mutation of the cleavage site, a 
mutation had been introduced in the region where the 
reactivity of KK16 was mapped”’ (position 619, C to 
G mutation). This did not influence the recognition of 
all the other Moabs, including those that recognize 
a conformation-dependent epitope, indicating that 
the overall conformational integrity of 8789-m had 
remained intact. 
The capacity of different adjuvants to enhance the 
antibody response was compared using the 8789-m 
envelope glycoprotein. This protein was selected on 
basis of its reactivity with KK5, KK9 and KK56 and its 
ability to induce high VN titres (Figures 4 and 5). The 
highest titres of SIV-specific antibodies were found in 
rats immunized with the 8789-m iscoms. This is in 
agreement with previous studies in which monkeys 
immunized with SIV proteins also showed a higher 
envelope antibody response with STV-envelope proteins 
incorporated into iscoms than adjuvanted with MDP’. 
However, in rabbits the HIV-l envelope protein adju- 
vanted with MDP-tsl was shown to induce a higher 
antibody response than HIV-l envelope protein incor- 
porated into the iscom matrix using a multiple immuniz- 
ation schedule ’ 6. This discrepancy may be due to the 
quality of the respective preparations, the animal species 
or to differences in the immunization schedule used. 
In conclusion, our results indicate that sequence 
changes occurring during in viva passage, result in major 
changes both in antigenicity and immunogenicity of the 
envelope glycoproteins of SIV. The availability of en- 
velope proteins with distinct variable regions may offer 
the possibility to study their protective value in vitro and 
in vivo against a wider range of virus variants, but may 
also offer the possibility of sequential immunization to 
prime and boost for an antibody response directed 
against conserved regions in the absence of a secondary 
immune response to variable regions. 
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